TY - JOUR T1 - Occurrence of angiographic femoral artery complications after vascular closure with Mynx and AngioSeal JF - Journal of NeuroInterventional Surgery JO - J NeuroIntervent Surg SP - 161 LP - 164 DO - 10.1136/neurintsurg-2011-010217 VL - 5 IS - 2 AU - Kyle M Fargen AU - Gregory J Velat AU - Matthew F Lawson AU - Charles A Ritchie AU - Christopher Firment AU - Brian L Hoh AU - Jeffery A Bennett AU - J Mocco Y1 - 2013/03/01 UR - http://jnis.bmj.com/content/5/2/161.abstract N2 - Introduction There have been recent reports of high vascular complication rates after the use of the Mynx vascular closure device (VCD). At our institution, vascular complications due to these devices have rarely been encountered. A study was undertaken to retrospectively compare angiographic abnormalities seen after femoral artery closure by both the Mynx and AngioSeal VCDs to provide further insight into the risks associated with VCDs. Methods All adult patients who underwent deployment of either a Mynx or AngioSeal VCD and subsequently underwent repeat angiography within the next 30 days between 1 July 2010 and 1 April 2011 were reviewed. Two independent blinded radiologists compared blinded pre-procedure and follow-up femoral angiograms for the presence of pseudoaneurysm or other vascular abnormality. Hospital records were reviewed for major or minor complications of the groin site or femoral artery. Results Thirty patients (31 angiograms) underwent vascular closure with a Mynx and 57 patients (69 angiograms) received an AngioSeal. The average time elapse until repeat femoral angiography was 6.2 days (range 1–21, median 5.5 days) in the Mynx group and 6.3 days (range 0–30, median 5 days) in the AngioSeal group. Two pseudoaneurysms and one minor stenosis were identified in the AngioSeal group. No angiographic abnormalities were seen in the Mynx group. No intraluminal filling defects were demonstrated on any of the follow-up femoral angiograms. One patient who received an AngioSeal developed a delayed minor groin site hematoma that did not require surgical intervention. Conclusions Angiographic complications were seen in only 3% of patients after closure with Mynx or AngioSeal VCDs. There were no clinically significant groin site or vascular complications. These data suggest that both VCDs are safe for use after angiography with a low rate of femoral artery complications. ER -